Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001) | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001)	Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease	Active, not recruiting	Phase 1	2025-12-05		NCT04184050

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	2

12 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Banner Md Anderson Cancer Center	Gilbert	United States	121
Centre Hospitalier Universitaire De Nantes	Nantes	France	13
Centre Hospitalier Universitaire de Poitiers	Poitiers	France	14
Hospital Universitario Fundacion Jimenez Diaz (UAM-FJD)	Madrid	Spain	1
Josep Carreras Leukaemia Research Institute	Barcelona	Spain	1
Mayo Clinic Arizona	Phoenix	United States	55
OHSU	Portland	United States	16
Roswell Park Comprehensive Cancer Center	Buffalo	United States	63
The University of Kansas Cancer Center	Fairway	United States	7
UC San Diego Moores Cancer Center	La Jolla	United States	199
University of Rochester James P Wilmot Cancer Institute	Rochester	United States	1
University of Washington - Seattle Cancer Center Alliance	Seattle	United States	1